Key Insights

• •

  Business leaders value design primarily for eliminating redundant processes and features, not just for innovation or empathy.

• •

  Michael Porter's concept of strategy as deciding what not to do aligns with focusing design efforts on elimination rather than only ideation.

• •

  Pharmaceutical research methods emphasize quickly failing ideas cheaply to avoid costly late-stage investments, a mindset applicable to UX innovation.

• •

  Integrated discovery involves shorter research cycles embedded in development, enabling continuous de-risking and quicker decision-making.

• •

  Large upfront discovery should be reserved for entering truly new or disruptive markets and requires strong executive support.

• •

  Pivoting research messaging from innovation generation to financial de-risking increases organizational buy-in amid rising capital costs.

• •

  Failing ideas early often meets resistance from product teams, especially during layoffs, but is critical to maximize research value.

• •

  Talking to non-customers and overserved market segments is crucial to identify disruptive ideas that existing customers may reject.

• •

  Quick concept tests using lightweight stimuli like press releases or storyboards can validate ideas and avoid expensive development.

• •

  Working closely with finance to model return on investments is essential as higher inflation demands higher returns to justify innovation spend.

Notable Quotes